Cancer clinical trials in the region Pays de la Loire

456 currently recruiting clinical trials
Region Pays de la Loire
Phase 3 Colon cancer Rectal cancer Anal cancer Pancreas cancer Liver and bile duct cancer Stomach and esophageal cancer Small intestine and appendix cancer #NCT07087054 #2024-519875-24-00
Required histologic types
Ileum cancer
Required histologic sub types
Neuroendocrine tumor
Required number of previous lines of therapy for current stage of disease
None
6 recruiting sites
Crinetics Pharmaceuticals Inc.
Phase 3 Breast cancer #NCT06103864 #2023-503675-24-00
Required HER2 statuses
HER2 Negative
Required HR statuses
HR Negative
Required disease stage
Metastatic
Required PDL1 statuses
PDL1 Positive (1% <= X < 25%) PDL1 Positive (25% <= X < 50%) PDL1 Positive (>= 50%)
Required number of previous lines of therapy for current stage of disease
None
Required previous treatments at advanced or metastatic stage
Systemic Treatment-Naive
8 recruiting sites
AstraZeneca
Phase 3 Colon cancer Rectal cancer #NCT07228832 #2025-521587-35-00
Required histologic sub types
Adenocarcinoma
Required disease stage
Metastatic
Required number of previous lines of therapy for current stage of disease
None
Required previous treatments at advanced or metastatic stage
Systemic Treatment-Naive
Excluded genetic anomalies
BRAF MSI/dMMR
Excluded previous treatments at localized stage
Immunotherapy Targeted therapy
Excluded previous treatments at advanced or metastatic stage
Immunotherapy Targeted therapy
10 recruiting sites
Summit Therapeutics
Phase 3 Acute leukemia #NCT07211958 #2025-522279-27-00
Required histologic types
Acute myeloid leukemia (AML)
Required central nervous system lesions
None Treated / Controled
Required genetic anomalies
NPM1
Required number of previous lines of therapy
None
Required previous treatments
Systemic Treatment-Naive
3 recruiting sites
Syndax Pharmaceuticals
Phase 3 Lymphoma CLL & Richter's syndrome #NCT06104566 #2023-508005-24-00
Required histologic types
B cell lymphoma CLL (Chronic Lymphocytic Leukemia)
Required histologic sub types
Lymphocytic lymphoma
Required number of previous lines of therapy
1
Required previous treatments
Targeted therapy
Excluded previous treatments
Systemic Treatment-Naive
12 recruiting sites
Ascentage Pharma Group Inc.
Phase 3 Breast cancer #NCT05696626 #2023-503708-10-00
Required HER2 statuses
HER2 Negative
Required HR statuses
HR Positive
Required disease stage
Locally Advanced Metastatic
Required genetic anomalies
ESR
Required number of previous lines of therapy for current stage of disease
1 2
Required previous treatments at advanced or metastatic stage
Targeted therapy Hormone therapy
Excluded genetic anomalies
Other mutation
Excluded previous treatments at advanced or metastatic stage
Systemic Treatment-Naive
13 recruiting sites
Sermonix Pharmaceuticals Inc.
Phase 3 Ovarian / Fallopian tubes / Peritoneum cancer #NCT07213804 #2025-522255-25-00
Partie A (Résistant au platine)
Required histologic types
Epithelial ovarian cancer Fallopian tube cancer Primary peritoneal cancer (PPC)
Required histologic sub types
Serous high grade carcinoma (HGSOC) Endometrioid carcinoma
Required number of previous lines of therapy for current stage of disease
1 2 3 or more
Required platino resistance
Recurrence within 6 months after platinum-based tr...
Required previous treatments at localized stage
Chemotherapy Targeted therapy
Required previous treatments at advanced or metastatic stage
Chemotherapy Targeted therapy
Excluded previous treatments at localized stage
Systemic Treatment-Naive
Excluded previous treatments at advanced or metastatic stage
Systemic Treatment-Naive
10 recruiting sites
Eli Lilly et compagnie
Phase 3 Ovarian / Fallopian tubes / Peritoneum cancer #NCT07213804 #2025-522255-25-00
Partie B (Sensible au platine avec traitement antérieur par Parpi)
Required histologic types
Epithelial ovarian cancer Fallopian tube cancer Primary peritoneal cancer (PPC)
Required histologic sub types
Serous high grade carcinoma (HGSOC) Endometrioid carcinoma
Required number of previous lines of therapy for current stage of disease
1 2
Required previous treatments at localized stage
Chemotherapy Targeted therapy
Required previous treatments at advanced or metastatic stage
Chemotherapy Targeted therapy
Excluded previous treatments at localized stage
Systemic Treatment-Naive
Excluded previous treatments at advanced or metastatic stage
Systemic Treatment-Naive
10 recruiting sites
Eli Lilly et compagnie
Phase 3 Ovarian / Fallopian tubes / Peritoneum cancer #NCT07213804 #2025-522255-25-00
Partie C (Sensible au platine naive de traitement par Parpi
Required histologic types
Epithelial ovarian cancer Fallopian tube cancer Primary peritoneal cancer (PPC)
Required histologic sub types
Serous high grade carcinoma (HGSOC) Endometrioid carcinoma
Required number of previous lines of therapy for current stage of disease
1 2
Required platino resistance
Recurrence 6 months or more after platinum treatme...
Required previous treatments at localized stage
Chemotherapy
Required previous treatments at advanced or metastatic stage
Chemotherapy
Excluded genetic anomalies
BRCA 1/2
Excluded previous treatments at localized stage
Systemic Treatment-Naive Targeted therapy
Excluded previous treatments at advanced or metastatic stage
Systemic Treatment-Naive Targeted therapy
10 recruiting sites
Eli Lilly et compagnie
Phase 3 Brain tumors / Central nervous system tumors #NCT05904119
Required histologic types
Gliomas
Required histologic sub types
Glioblastoma
Required number of previous lines of therapy
1
Required previous treatments
Surgery Radiochemotherapy
Excluded genetic anomalies
IDH1/2
Excluded previous treatments
Systemic Treatment-Naive
10 recruiting sites
EORTC - Organisation Européenne pour la Recherche et le Traitement du Cancer